Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory single-center trial of CL2020 in amyotrophic lateral sclerosis
jRCT2063200047Completed
- Sponsor
- Life Science Institute
- Start
- Feb 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of CL2020 in amyotrophic lateral sclerosis (ALS), sponsored by Life Science Institute. Primary endpoint: Safety and tolerability. Started Feb 2021; status: completed.
02
Drugs
CL2020
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2063200047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063200047.